Y-Intercept (HK)’s ACELYRIN SLRN Stock Holding History

Y-Intercept (HK)’s Portfolio SLRN Stock Details SLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-20,565	Closed	-$153K	–	1729
2023 Q4	$153K	Buy	+20,565	New	+$176K	0.01%	1047

Other funds holding SLRN

ACMC

AyurMaya Capital Management Company Portsmouth, New Hampshire $148M AUM 24.4% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Y-Intercept (HK)'s SLRN Position: Q1 2024 in Review

Y-Intercept (HK) sold out of ACELYRIN (SLRN) in Q1 2024, closing a stake of 20,565 shares — an estimated $153K sold.

Y-Intercept (HK) first reported a position in SLRN in Q4 2023 and held it in 1 quarter. The position peaked at $153K in Q4 2023. 109 funds tracked by Wall St. Rank hold SLRN as of Q1 2024.

Y-Intercept (HK) reported no remaining ACELYRIN position as of Q1 2024 after selling out during the quarter.
Y-Intercept (HK) sold 20,565 ACELYRIN shares in Q1 2024, an estimated $153K.
Y-Intercept (HK) first reported a position in ACELYRIN in Q4 2023 and held it in 1 quarter.
Y-Intercept (HK)'s ACELYRIN position peaked at $153K in Q4 2023.
109 funds tracked by Wall St. Rank held ACELYRIN as of Q1 2024.

Based on Y-Intercept (HK)'s 13F filing for Q1 2024, filed 10 May 2024.